McPherron Aviva sold $34K of OFIX

McPherron Aviva (Pres, Global Ops & Qual) sold 3,670 shares of Orthofix Medical Inc. (OFIX) at $9.38 on 2026-06-18.

Original reporting
SEC EDGAR · McPherron Aviva
Published Jun 22, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Neutral
high confidence
Mentioned
$OFIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

A single officer open-market sale of ~$34.4K is disclosed; it does not include new operational, financial, or regulatory information.

02

Market read

Traders may note insider activity, but the disclosed transaction size and lack of additional company-specific news suggest limited trading edge.

03

What to watch

The article does not state tax/portfolio rationale, whether the sale was part of a broader pattern, or any concurrent company news; without that context, signal quality is low.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-22; sale executed 2026-06-18.

Background

The article is an SEC Form 4 insider transaction disclosure for Orthofix Medical Inc.

Company-level read

Ticker impact

$OFIXNeutralHigh confidence
Context

Orthofix Medical insider McPherron Aviva sold 3,670 shares on 2026-06-18 at $9.38/share for ~$34.4K, per Form 4.

Expected impact

Minimal near-term impact; any effect is likely short-lived and outweighed by normal trading noise.

Evidence & confidence

The filing is a small, non-accelerated sale by an officer with no 10b5-1 plan disclosed; size is modest and does not indicate a new corporate event.

Market effects

No sector-level read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can sometimes precede negative developments, but this disclosure lacks any accompanying catalyst or guidance change.

Key entities

  • Orthofix Medical Inc.

    Company whose insider transaction is reported on Form 4.

  • McPherron Aviva

    Pres, Global Ops & Qual who sold 3,670 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte